Suggested remit: to appraise the clinical and cost effectiveness of mirikizumab within its marketing authorisation for treating moderately to severely active Crohn’s disease.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6244

Project Team

Project lead Jennifer Upton

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Timeline

Key events during the development of the guidance:

Date Update
24 September 2024 Following an update from the company, we have paused this appraisal to align with regulatory timelines.
14 May 2024 Invitation to participate
17 January 2024 - 14 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6244
17 January 2024 In progress. Scoping commenced.
31 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual